Skip to main content
Erschienen in:

01.10.2006 | Current Status

Efficacy of Oral Anticancer Agents for Colorectal Cancer

verfasst von: Junichi Sakamoto, M.D., Ph.D., Koji Oba, M.S., Takanori Matsui, M.D., Ph.D., Michiya Kobayashi, M.D., Ph.D.

Erschienen in: Diseases of the Colon & Rectum | Sonderheft 1/2006

Einloggen, um Zugang zu erhalten

Excerpt

Development of oral anticancer agents was long awaited by both physicians and patients. It can be taken for granted that most patients prefer oral intake to injection of such drugs if the efficacy of the former is equivalent or superior to that of parenteral agents.1 In terms of quality of life and cost-effectiveness, oral agents are obviously superior to parenteral drugs, which necessitate hospitalization or a long stay in the outpatient ward for their injection. …
Literatur
1.
Zurück zum Zitat Borner, MM, Schoffski, P, Wit, R, et al. 2002Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerEur J Cancer38349358PubMedCrossRef Borner, MM, Schoffski, P, Wit, R,  et al. 2002Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancerEur J Cancer38349358PubMedCrossRef
2.
Zurück zum Zitat Hahn, RG, Moertel, CG, Schutt, AJ, Bruckner, HW 1975A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinomaCancer3510311035PubMedCrossRef Hahn, RG, Moertel, CG, Schutt, AJ, Bruckner, HW 1975A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinomaCancer3510311035PubMedCrossRef
3.
Zurück zum Zitat Friedman, MA, Ignoffo, RJ 1980A review of the United States clinical experience of the fluoropyridimine, Ftorafur (NSC-148958)Cancer Treat Rev7205213PubMedCrossRef Friedman, MA, Ignoffo, RJ 1980A review of the United States clinical experience of the fluoropyridimine, Ftorafur (NSC-148958)Cancer Treat Rev7205213PubMedCrossRef
4.
Zurück zum Zitat Sakamoto, J, Hamada, C, Kodaira, S, Nakazato, H, Ohashi, Y 1999Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trialsJpn J Clin Oncol297886PubMedCrossRef Sakamoto, J, Hamada, C, Kodaira, S, Nakazato, H, Ohashi, Y 1999Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trialsJpn J Clin Oncol297886PubMedCrossRef
5.
Zurück zum Zitat Hoshi, A, Iigo, M, Yoshida, M, Kuretani, K 1975Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administrationGann66673674PubMed Hoshi, A, Iigo, M, Yoshida, M, Kuretani, K 1975Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administrationGann66673674PubMed
6.
Zurück zum Zitat Hoshi, A, Iigo, M, Nakamura, A, Yoshida, M, Kuretani, K 1976Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumorsGann67725731PubMed Hoshi, A, Iigo, M, Nakamura, A, Yoshida, M, Kuretani, K 1976Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumorsGann67725731PubMed
7.
Zurück zum Zitat HCFU Clinical Study Group1980Absorption and excretion of new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patientsJpn J Clin Oncol108392 HCFU Clinical Study Group1980Absorption and excretion of new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patientsJpn J Clin Oncol108392
8.
Zurück zum Zitat Iigo, M, Hoshi, A, Nakamura, A, Kuretani, K 1978Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumorsCancer Chemother Pharmacol1203208PubMedCrossRef Iigo, M, Hoshi, A, Nakamura, A, Kuretani, K 1978Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumorsCancer Chemother Pharmacol1203208PubMedCrossRef
9.
Zurück zum Zitat Koyama, Y 19811-hexylcarbamoyl-5-fluorouracil (HCFU): a masked 5-fluorinated pyrimidineCancer Treat Rev8147156PubMed Koyama, Y 19811-hexylcarbamoyl-5-fluorouracil (HCFU): a masked 5-fluorinated pyrimidineCancer Treat Rev8147156PubMed
11.
Zurück zum Zitat Kono, A, Hara, Y, Sugata, S, Karube, Y, Matsushima, Y, Ishitsuka, H 1983Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumorsChem Pharm Bull (Tokyo)31175178 Kono, A, Hara, Y, Sugata, S, Karube, Y, Matsushima, Y, Ishitsuka, H 1983Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumorsChem Pharm Bull (Tokyo)31175178
12.
Zurück zum Zitat Kikkawa, N, Taguchi, T, Sakai, K, et al. 1993Combination therapy of high dose doxifluridine (5′-DFUR) + mitomycin C (MMC) for advanced or recurrent colorectal cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5′-DFUR with Other Drugs [in Japanese]Gan To Kagaku Ryoho20117123PubMed Kikkawa, N, Taguchi, T, Sakai, K,  et al. 1993Combination therapy of high dose doxifluridine (5′-DFUR) + mitomycin C (MMC) for advanced or recurrent colorectal cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5′-DFUR with Other Drugs [in Japanese]Gan To Kagaku Ryoho20117123PubMed
13.
Zurück zum Zitat Malik, ST, Talbot, D, Clarke, PI, et al. 1990Phase II trial of UFT in advanced colorectal and gastric cancerBr J Cancer6210231025PubMed Malik, ST, Talbot, D, Clarke, PI,  et al. 1990Phase II trial of UFT in advanced colorectal and gastric cancerBr J Cancer6210231025PubMed
14.
Zurück zum Zitat Ota, K, Taguchi, T, Kimura, K 1987Report on nationwide pooled data and cohort investigation in UFT Phase II study [in Japanese]Gan To Kagaku Ryoho1427492757PubMed Ota, K, Taguchi, T, Kimura, K 1987Report on nationwide pooled data and cohort investigation in UFT Phase II study [in Japanese]Gan To Kagaku Ryoho1427492757PubMed
15.
Zurück zum Zitat Pazdur, R, Lassere, Y, Diaz-Canton, E, Ho, DH 1998Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day scheduleCancer Invest16145151PubMed Pazdur, R, Lassere, Y, Diaz-Canton, E, Ho, DH 1998Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day scheduleCancer Invest16145151PubMed
16.
Zurück zum Zitat Anonymous1992Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis ProjectJ Clin Oncol10896903 Anonymous1992Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis ProjectJ Clin Oncol10896903
17.
Zurück zum Zitat Pazdur, R, Lassere, Y, Rhodes, V, et al. 1994Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinomaJ Clin Oncol1222962300PubMed Pazdur, R, Lassere, Y, Rhodes, V,  et al. 1994Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinomaJ Clin Oncol1222962300PubMed
18.
Zurück zum Zitat Ichikawa, W, Nihei, Z, Uetake, H, Yamada, H, Shirota, Y, Sugihara, K 2000UFT plus leucovorin for metastatic colorectal cancer: Japanese experienceOncology (Williston Park)144143 Ichikawa, W, Nihei, Z, Uetake, H, Yamada, H, Shirota, Y, Sugihara, K 2000UFT plus leucovorin for metastatic colorectal cancer: Japanese experienceOncology (Williston Park)144143
19.
Zurück zum Zitat Carmichael, J, Popiela, T, Radstone, D, et al. 2002Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol2036173627PubMedCrossRef Carmichael, J, Popiela, T, Radstone, D,  et al. 2002Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol2036173627PubMedCrossRef
20.
Zurück zum Zitat Douillard, J-Y, Hoff, PM, Skillings, JR, et al. 2002Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol2036053616PubMedCrossRef Douillard, J-Y, Hoff, PM, Skillings, JR,  et al. 2002Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol2036053616PubMedCrossRef
21.
Zurück zum Zitat Shirao, K, Hoff, PM, Ohtsu, A, et al. 2004Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LVJ Clin Oncol2234663474PubMedCrossRef Shirao, K, Hoff, PM, Ohtsu, A,  et al. 2004Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LVJ Clin Oncol2234663474PubMedCrossRef
22.
Zurück zum Zitat Miwa, M, Ura, M, Nishida, M, et al. 1998Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEur J Cancer3412741281PubMedCrossRef Miwa, M, Ura, M, Nishida, M,  et al. 1998Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissueEur J Cancer3412741281PubMedCrossRef
23.
Zurück zum Zitat Takebayashi, Y, Akiyama, S, Akiba, S, et al. 1996Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinomaJ Natl Cancer Inst8811101117PubMed Takebayashi, Y, Akiyama, S, Akiba, S,  et al. 1996Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinomaJ Natl Cancer Inst8811101117PubMed
24.
Zurück zum Zitat Cutsem, E, Findlay, M, Osterwalder, B, et al. 2000Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II studyJ Clin Oncol1813371345PubMed Cutsem, E, Findlay, M, Osterwalder, B,  et al. 2000Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II studyJ Clin Oncol1813371345PubMed
25.
Zurück zum Zitat Cutsem, E, Twelves, C, Cassidy, J, et al. 2001Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyJ Clin Oncol1940974106PubMed Cutsem, E, Twelves, C, Cassidy, J,  et al. 2001Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyJ Clin Oncol1940974106PubMed
26.
Zurück zum Zitat Hoff, PM, Ansari, R, Batist, G, et al. 2001Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyJ Clin Oncol1922822292PubMed Hoff, PM, Ansari, R, Batist, G,  et al. 2001Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyJ Clin Oncol1922822292PubMed
27.
Zurück zum Zitat Cassidy, J, Tabernero, J, Twelves, C, et al. 2004XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJ Clin Oncol2220842091PubMedCrossRef Cassidy, J, Tabernero, J, Twelves, C,  et al. 2004XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJ Clin Oncol2220842091PubMedCrossRef
28.
Zurück zum Zitat Scheithauer, W, Kornek, GV, Raderer, M, et al. 2003Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol2113071312PubMedCrossRef Scheithauer, W, Kornek, GV, Raderer, M,  et al. 2003Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol2113071312PubMedCrossRef
29.
Zurück zum Zitat Feliu, J, Escudero, P, Llosa, F, et al. 2005Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group studyJ Clin Oncol2331043111PubMedCrossRef Feliu, J, Escudero, P, Llosa, F,  et al. 2005Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group studyJ Clin Oncol2331043111PubMedCrossRef
30.
Zurück zum Zitat Hofheinz, RD, Gerstenberg-Helldorf, B, Wenz, F, et al. 2005Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancerJ Clin Oncol2313501357PubMedCrossRef Hofheinz, RD, Gerstenberg-Helldorf, B, Wenz, F,  et al. 2005Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancerJ Clin Oncol2313501357PubMedCrossRef
31.
Zurück zum Zitat Shirasaka, T, Shimamato, Y, Ohshimo, H, et al. 1996Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnticancer Drugs7548557PubMedCrossRef Shirasaka, T, Shimamato, Y, Ohshimo, H,  et al. 1996Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnticancer Drugs7548557PubMedCrossRef
32.
Zurück zum Zitat Tatsumi, K, Fukushima, M, Shirasaka, T, Fujii, S 1987Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extractsJpn J Cancer Res78748755PubMed Tatsumi, K, Fukushima, M, Shirasaka, T, Fujii, S 1987Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extractsJpn J Cancer Res78748755PubMed
33.
Zurück zum Zitat Groeningen, CJ, Peters, GJ, Schornagel, JH, et al. 2000Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumorsJ Clin Oncol1827722779PubMed Groeningen, CJ, Peters, GJ, Schornagel, JH,  et al. 2000Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumorsJ Clin Oncol1827722779PubMed
34.
Zurück zum Zitat Hoff, PM, Saad, ED, Ajani, JA, et al. 2003Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumorsClin Cancer Res9134142PubMed Hoff, PM, Saad, ED, Ajani, JA,  et al. 2003Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumorsClin Cancer Res9134142PubMed
35.
Zurück zum Zitat Chu, QS, Hammond, LA, Schwartz, G, et al. 2004Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesClin Cancer Res1049134921PubMedCrossRef Chu, QS, Hammond, LA, Schwartz, G,  et al. 2004Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesClin Cancer Res1049134921PubMedCrossRef
36.
Zurück zum Zitat Brande, J, Schoffski, P, Schellens, JH, et al. 2003EORTC Early Clinical Studies Group. Early phase II trial of S-1 in patients with advanced or metastatic colorectal cancerBr J Cancer88648653PubMedCrossRef Brande, J, Schoffski, P, Schellens, JH,  et al. 2003EORTC Early Clinical Studies Group. Early phase II trial of S-1 in patients with advanced or metastatic colorectal cancerBr J Cancer88648653PubMedCrossRef
37.
Zurück zum Zitat Taguchi, T, Inuyama, Y, Kanamaru, R, et al. 1997Phase I study of S-1. S-1 Study Group [in Japanese]Gan To Kagaku Ryoho2422532264PubMed Taguchi, T, Inuyama, Y, Kanamaru, R,  et al. 1997Phase I study of S-1. S-1 Study Group [in Japanese]Gan To Kagaku Ryoho2422532264PubMed
38.
Zurück zum Zitat Ohtsu, A, Baba, H, Sakata, Y, et al. 2000Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupBr J Cancer83141145PubMedCrossRef Ohtsu, A, Baba, H, Sakata, Y,  et al. 2000Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study GroupBr J Cancer83141145PubMedCrossRef
39.
Zurück zum Zitat Shirao, K, Ohtsu, A, Takada, H, et al. 2004Phase II study of oral S-1 for treatment of metastatic colorectal carcinomaCancer10023552361PubMedCrossRef Shirao, K, Ohtsu, A, Takada, H,  et al. 2004Phase II study of oral S-1 for treatment of metastatic colorectal carcinomaCancer10023552361PubMedCrossRef
40.
Zurück zum Zitat Komatsu, Y, Yuuki, S, Fuse, N, et al. 2005Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302Jpn J Clin Oncol358889PubMedCrossRef Komatsu, Y, Yuuki, S, Fuse, N,  et al. 2005Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302Jpn J Clin Oncol358889PubMedCrossRef
41.
Zurück zum Zitat Matsuda, T, Yasutomi, M, Kikuchi, K, et al. 1991Cooperative study of surgical adjuvant chemotherapy for colorectal cancer: five year results [in Japanese]Gan To Kagaku Ryoho18461469PubMed Matsuda, T, Yasutomi, M, Kikuchi, K,  et al. 1991Cooperative study of surgical adjuvant chemotherapy for colorectal cancer: five year results [in Japanese]Gan To Kagaku Ryoho18461469PubMed
42.
Zurück zum Zitat Anonymous1995Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of JapanJpn J Clin Oncol2591103 Anonymous1995Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of JapanJpn J Clin Oncol2591103
43.
Zurück zum Zitat Ito, K, Yamaguchi, A, Miura, K, et al. 1996Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-upJ Surg Oncol63107111PubMedCrossRef Ito, K, Yamaguchi, A, Miura, K,  et al. 1996Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-upJ Surg Oncol63107111PubMedCrossRef
44.
Zurück zum Zitat Sakamoto, J, Hamada, C, Kodaira, S, Nakazato, H, Ohashi, Y 1999Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trialsJpn J Clin Oncol297886PubMedCrossRef Sakamoto, J, Hamada, C, Kodaira, S, Nakazato, H, Ohashi, Y 1999Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trialsJpn J Clin Oncol297886PubMedCrossRef
45.
Zurück zum Zitat Sakamoto, J, Kodaira, S, Hamada, C, et al. 2001An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancerOncol Rep8697703PubMed Sakamoto, J, Kodaira, S, Hamada, C,  et al. 2001An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancerOncol Rep8697703PubMed
46.
Zurück zum Zitat Sakamoto, J, Ohashi, Y, Hamada, C, et al. 2004Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trialsJ Clin Oncol22484492PubMed Sakamoto, J, Ohashi, Y, Hamada, C,  et al. 2004Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trialsJ Clin Oncol22484492PubMed
47.
Zurück zum Zitat Kodaira, S, Kikuchi, K, Yasutomi, M, et al. 1998Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer: results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of CancerInt J Clin Oncol3357364CrossRef Kodaira, S, Kikuchi, K, Yasutomi, M,  et al. 1998Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer: results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of CancerInt J Clin Oncol3357364CrossRef
48.
Zurück zum Zitat Yasutomi, M, Takahashi, T, Kodaira, S, et al. 1997Prospective controlled study of the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancerGan To Kagaku Ryoho2419531960PubMed Yasutomi, M, Takahashi, T, Kodaira, S,  et al. 1997Prospective controlled study of the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancerGan To Kagaku Ryoho2419531960PubMed
49.
Zurück zum Zitat Wolmark, N, Colangelo, L, Wieand, S 2001National Surgical Adjuvant Breast and Bowel Project trials in colon cancerSemin Oncol28913PubMedCrossRef Wolmark, N, Colangelo, L, Wieand, S 2001National Surgical Adjuvant Breast and Bowel Project trials in colon cancerSemin Oncol28913PubMedCrossRef
50.
Zurück zum Zitat Wolmark, N, Wieand, S, Lembersky, B, Colangelo, L, Smith, R, Pazdur, R 2004A Phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06Proc Am Soc Clin Oncol (Post-Meeting Edition)22247 Wolmark, N, Wieand, S, Lembersky, B, Colangelo, L, Smith, R, Pazdur, R 2004A Phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06Proc Am Soc Clin Oncol (Post-Meeting Edition)22247
51.
Zurück zum Zitat Akasu, T, Moriya, Y, Yoshida, S, et al. 2004Adjuvant oral uracil and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC): results of the National Surgical Adjuvant Study (NSAS)-Colorectal Cancer (CC) 01 randomized trialProc Am Soc Clin Oncol (Post-Meeting Edition)22251 Akasu, T, Moriya, Y, Yoshida, S,  et al. 2004Adjuvant oral uracil and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC): results of the National Surgical Adjuvant Study (NSAS)-Colorectal Cancer (CC) 01 randomized trialProc Am Soc Clin Oncol (Post-Meeting Edition)22251
52.
Zurück zum Zitat Sakamoto, J, Hamada, C, Yasutomi, M, et al. 2005An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancerJpn J Clin Oncol35536544PubMedCrossRef Sakamoto, J, Hamada, C, Yasutomi, M,  et al. 2005An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancerJpn J Clin Oncol35536544PubMedCrossRef
53.
Zurück zum Zitat Twelves, C, Wong, A, Nowacki, MP, et al. 2005Capecitabine as adjuvant treatment for stage III colon cancerN Engl J Med3522696704PubMedCrossRef Twelves, C, Wong, A, Nowacki, MP,  et al. 2005Capecitabine as adjuvant treatment for stage III colon cancerN Engl J Med3522696704PubMedCrossRef
Metadaten
Titel
Efficacy of Oral Anticancer Agents for Colorectal Cancer
verfasst von
Junichi Sakamoto, M.D., Ph.D.
Koji Oba, M.S.
Takanori Matsui, M.D., Ph.D.
Michiya Kobayashi, M.D., Ph.D.
Publikationsdatum
01.10.2006
Erschienen in
Diseases of the Colon & Rectum / Ausgabe Sonderheft 1/2006
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-006-0601-7

Weitere Artikel der Sonderheft 1/2006

Diseases of the Colon & Rectum 1/2006 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Cold-Snare- kann Hot-Snare-Polypektomie kaum ersetzen

Bei der Abtragung größerer ungestielter Darmpolypen lohnt es sich, weiterhin der Hot-Snare-Technik zu vertrauen. Damit kommt es zwar etwas häufiger zu Komplikationen, dafür wesentlich seltener zu endoskopischen Rezidiven.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Vier Kriterien sprechen für ein erhöhtes Risiko nach Appendektomie

17.07.2024 Appendektomie Nachrichten

Um bei Kindern den Schweregrad einer Appendizitis und drohende Komplikationen richtig einzuschätzen, können sich Chirurginnen und Chirurgen auf die intraoperativen Kriterien des US-amerikanischen NSQIP Pediatric stützen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.